TACKLE MESOTHELIOMA

Temsirolimus and Cisplatin offer new way of treating malignant pleural mesothelioma

Key points:
- Temsirolimus gives a new way of treating malignant pleural mesothelioma
- Temsirolimus is a kinase inhibitor used to treat advanced renal cell carcinoma (RCC)
- The conclusion was published in the Journal of Oncology Reports
- Temsirolimus works against mesothelioma cells by blocking the action of a gene pathway called mammalian target of rapamycin (mTOR)
- Temsirolimus can also be used to prevent the formation of blood vessels that are needed to grow a tumor cell
- The study suggested the combined treatment to mesothelioma by using temsirolimus and cisplatin

By PRWeb
A new study published in the journal Oncology Reports and detailed by Surviving Mesothelioma suggests that temsirolimus, a kinase inhibitor used to treat advanced renal cell carcinoma (RCC), may offer a promising new way to treat malignant pleural mesothelioma.

The group studied temsirolimus by itself and in combination with the popular mesothelioma chemotherapy drugs cisplatin or pemetrexed against cell samples from five different mesothelioma cell lines. They then used a series of highly sensitive chemical tests to determine exactly what effect the temsirolimus had on the cells and why.

Temsirolimus appeared to work against the mesothelioma cells in two different ways. By blocking the action of a gene pathway called mammalian target of rapamycin (mTOR), which is highly expressed in some mesothelioma lines, temsirolimus makes it harder for cancer cells to grow and divide. At the same time, the drug also acts on two other compounds – vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) – to prevent the formation of blood vessels (angiogenesis) needed to feed a growing tumor.

Although temsirolimus alone inhibited cell viability and suppressed cell proliferation in all of the mesothelioma cell lines tested, combining it with another drug enhanced the effect. “Combined treatment with temsirolimus and cisplatin inhibited the viability of all malignant pleural mesothelioma cell lines more effectively than temsirolimus alone,” the authors report. Noting that temsirolimus fights mesothelioma on two different levels, they suggest that It may give patients an advantage, especially if they have high mTOR expression.

Mesothelioma is a rare but highly-lethal cancer caused almost exclusively by exposure to asbestos. Most people diagnosed with this aggressive malignancy do not live longer than a year after diagnosis. For this reason, researchers around the world are actively testing drugs like temsirolimus that may offer an alternative ways to treat the disease or make current treatments more effective.

The original study on temsirolimus was published in a recent issue of Oncology Reports. (Moriva, M, et al, “Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma”, December 30, 2013, Oncology Reports, Epub ahead of print. http://www.ncbi.nlm.nih.gov/pubmed/24378576)

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Pineapples’ Bromelain as a therapeutic agent in malignant peritoneal mesothelioma

Key points to remember:
- Pineapples or Bromelain could improve the treatment of Mesothelioma
- The statement was concluded by a study in Australia
- The study was published by the Journal of AntiCancer Drugs
- The addition of bromelain increased the cytotoxicity of cisplatin significantly in both cell lines
- Bromelain have the ability to break down MUC-1 in mesothelioma cells through a chemical decomposition process called hydrolyses.
- Bromelain triggered apoptosis (programmed cell death) and autophagy (breakdown of the component parts of cells) in several mesothelioma cell lines.
- Bromelain has the potential of being developed as a therapeutic agent in malignant peritoneal mesothelioma.

By PRWeb
A study conducted in Australia and reported by Surviving Mesothelioma finds that a compound derived from the stems of pineapples appears to be able to improve standard drug treatment for peritoneal mesothelioma.

Bromelain has a history of use in folk medicine and is believed to have anti-inflammatory effects. Previous studies have found it to have a negative effect on some pancreatic and breast cancer cells but researchers at the University New South Wales are the first to publish research on bromelain’s ability to enhance cisplatin treatment for mesothelioma. Writing in the journal AntiCancer Drugs, they report, “The addition of bromelain increased the cytotoxicity of cisplatin significantly in both cell lines.”

The research focused on a protein called MUC-1. Found in several mesothelioma cell lines, MUC-1 makes it possible for cancer cells to spread and invade other areas of the body and to resist the toxic effects of chemotherapy drugs. But bromelain appears to have the ability to break down MUC-1 in mesothelioma cells through a chemical decomposition process called hydrolyses.

In the new study, different mesothelioma cell lines were treated with various concentrations of bromelain. Their viability was assessed after 4 and 72 hours. The researchers found that bromelain triggered apoptosis (programmed cell death) and autophagy (breakdown of the component parts of cells) in several mesothelioma cell lines. Although the compound did not increase the toxicity of a cancer treatment called 5-FU, it did make cisplatin more effective. Along with pemetrexed, the platinum-based drug cisplatin is the most common drug treatment for mesothelioma.

The new study is the second published study on bromelain and mesothelioma from the same group of scientists. They conclude that “Bromelain has the potential of being developed as a therapeutic agent in malignant peritoneal mesothelioma.” Organized human trials will be needed before bromelain can be incorporated into mesothelioma treatment. Doctors discourage patients from attempting to self-medicate with supplements.

The study was published in Anti-Cancer Drugs. (Pillai, K, et al, “Anticancer effect of bromelain with and without cisplatin or 5-FU on malignant peritoneal mesothelioma cells”, February 25, 2014, pp. 150-160.

Asons Solicitors: Penelitian terbaru hasilkan uji deteksi kanker Mesothelioma terbaru sejak dini

TackleMesothelioma.Blogspot.com – Penelitian tersebut dikeluarkan oleh Clinical Proteomics Journal pada 8 November 2013 oleh satu tim peneliti internasional yang terdiri dari Fedinando Cerciello dan Bern Wollscheid from Institut Biologi Molekul di Zurich. (1)

Tim peneliti tersebut menggunakan teknologi Selected Reaction Monitoring-SRM (Pengawasan Reaksi Pilihan untuk mengungkap tanda-tanda khusus dari protein mesothelioma. Sebagaimana dilaporkan, tim peneliti tersebut mengungkapkan bahwa:

“Hasil evaluasi kami terhadap 51 kandidat biomaker dalam suatu rangkaian validasi eksperimen dan validasi independen mengungkap adanya suatu tanda glycopeptide (glikopeptida) yang bisa berkembang biak dalam suatu produk serum yang biasa melengkapi biomaker mesothelioma. (1)

Uji SRM sendiri didasarkan pada hipotesa bahwa sel-sel tumor rentan meleppaskan glycoproteins ke dalam sistem peredaran darah. Setelah memperhatikan secara seksama pada permukaan garis sel mesothelioma yang berpotensi mengandung kandidat biomaker, maka tim tersebut mendesain suatu alat uji yang akan digunakan untuk memindai protein khusus yang dapat ditemukan dalam serum manusia. (1)

Kesimpulan penelitian tersebut berbunyi:

“Hasil penelitian kami menunjukkan bahwa teknologi SRM mampu melakukan evaluasi klinis secara langsung terhadap kandidat biomaker yang berasal dari kandungan protein mesothelioma. (1)

Menurut statistik terbaru, yang dikeluarkan oleh Health and Safety Executive-HSE, angka kematian akibat kanker mesothelioma dalam setahun diperkirakan semakin meningkat di tahun-tahun mendatang, dengan puncaknya diperkirakan pada akhir dekade ini. (2)

Mesothelioma adalah salah satu bentuk kanker yang disebabkan oleh menghirup dan mengakumulasi serat asbes di dalam paru-paru. Namun sayang, gejala mesothelioma biasanya baru muncul setelah mengidap kanker tersebut selama 50 tahun, atau ketika kanker tersebut semakin parah. Jika temuan penelitian ini dapat dikonfirmasi, maka inilah cara yang paling mungkin untuk mendeteksi kanker mesothelioma melalui tes darah yang mudah dan praktis.

Asons Solicitors telah membentuk tim spesialis yang bertugas untuk menangangi penggunaan asbes dan penyakit yang disebabkan oleh asbes, dengan memberikan bantuan hukum khususnya untuk kasus kanker mesothelioma.

Eksposur terhadap asbes dapat menjadi sesuatu yang berbahaya, dan Asos menyeru siapa saja yang merasa telah terekspose dengan serat asbes agar mengkonsultasikan kondisinya secepat mungkin. Untuk mendapatkan informasi lebih lanjut tentang kasus klaim asbes dan cara mendapatkan kompensasi dari kanker mesothelioma, hubungi Asons di situs: http://www.asons.co.uk atau dengan menghubungi 01204 521 133.

1. Clinical Proteomics Journal – Identifikasi tujuh tanda glycopeptide bagi kanker mesothelioma di serum manusia dengan Pengawasan Reaksi Pilihan
2. HSE – Mesothelioma

English to Bahasa Indonesia translation by Irfan Translator Pro

Original source: http://www.prweb.com/releases/2013/11/prweb11379031.htm

Subsequent HIPEC Treatment Improves Mesothelioma Survival Says Researchers

If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery.

The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution of chemotherapy drugs to kill as many residual cancer cells as possible.

The new study focused on 29 patients who underwent surgery for peritoneal mesothelioma at Moffitt between June 2004 and March 2012. All but three of these patients also had the HIPEC treatment right after surgery. Of these, 8 patients returned later to have a second HIPEC procedure in an effort to slow or stop the regrowth of their mesothelioma.

Read the full article at: http://www.survivingmesothelioma.com/news/view.asp?ID=001551#.Un2pilNYWSo

Percobaan Perawatan terhadap Mesothelioma Cancer Dimulai

Puluhan tahun silam, ilmuan dan praktisi medis telah memahami bahwa menghirup serat asbestos adalah penyebab mesothelioma cancer yang berkembang di dalam dinding dada manusia.

Hingga hari ini, para praktisi medis juga terus berusaha menemukan perawatan yang tepat untuk meningkatkan dan memperpanjang harapan hidup pasien penderita kanker mesothelioma.

Awal tahun ini, peneliti dari University of Leicester, Inggris mengumumkan bahwa mereka akan segera memulai percobaan dua metode perawatan kanker paru-paru ganas yang disebabkan oleh asbestos ini.

Percobaan pertama adalah perawatan terhadap pasien kanker mesothelioma dengan suatu obat yang disebut dengan ganetespib, yang diproduksi sedemikian rupa untuk menghindari produksi protein khusus dalam sel-sel tubuh.

Proten tersebut, yang dikenal dengan HSP 90, merupakan protein yang diperlukan untuk produksi protein lain yang merupakan pemicu tumbuhnya tumor. Terdapat sekitar 140 pasien mesothelioma di Inggris yang terlibat dalam percobaan genetespib ini.

Metode perawatan terhadap pasien penderita kanker mesothelioma selanjutnya adalah dengan menggunakan obat defactinib. Obat ini diracik untuk menghambat produksi protein Focal Adhesion Kinase (FAK).

FAK berperan penting dalam perkembangan Mesothelioma cancer dalam fungsinya sebagai perekat dan penyebar sel-sel kanker ke seluruh tubuh manusia. FAK juga memiliki peran krusial pada perkembangan mesothelioma cancer terutama pada pasien yang pernah menjalani chemotherapy.(Digitaljournal)

Operasi Kanker Mesothelioma Diragukan Keampuhannya

Penelitian terbaru yang dilakukan di Italia dan disajikan pada Konferensi Dunia ke-15 mengenai Kanker Paru-paru di Sydney, Australia menunjukkan bahwa operasi mesothelioma – apapun itu jenis operasinya - tidak menawarkan manfaat bagi kelangsungan hidup untuk pasien.

Mesothelioma adalah kanker ganas yang langka tapi agresif yang sangat tahan terhadap pengobatan kanker standar. Dua jenis operasi mesothelioma dianggap pilihan untuk penderita kanker dioperasi adalah pleurectomy decortication (P/D) atau pneumonectomy extrapleural (EPP). Sementara EPP dianggap lebih radikal daripada P/D karena memiliki risiko berat terjadinya komplikasi dan, menurut para peneliti Italia, mungkin tidak berguna apa-apa untuk pasien.

Penelitian ini meninjau data dari 1.365 pasien berturut-turut dengan histologi dikonfirmasi mesothelioma rongga dada ganas. Pasien tersebut mendapat perawatan kanker mesothelioma antara 1982 dan 2012. Dari 1.365 pasien, 503 diobati dengan operasi. prosedur P/D dilakukan pada 202 pasien dan EPP digunakan untuk 301 pasien lainnya. Beberapa pasien bedah juga menjalani kemoterapi untuk mesothelioma. Agar dapat dianggap memenuhi syarat untuk operasi, pasien harus memiliki faktor prognosis yang baik dan berada dalam kesehatan yang baik secara keseluruhan.

Para pasien yang tidak menjalani operasi mesothelioma atau kemoterapi (172 pasien) atau perawatan suportif terbaik ( 690 pasien ), tujuan yang manajemen gejala saja. Semua pasien diikuti selama minimal satu tahun , kecuali mereka meninggal sebelum tahun naik .

Awalnya, tampak seolah-olah pasien yang menjalani operasi memiliki hasil yang lebih baik daripada mereka yang tidak. Pasien mesothelioma yang telah mendapat perawatan paliatif atau kemoterapi memiliki hidup rata-rata 11,7 bulan, pasien P/D memiliki hidup rata-rata 20,5 bulan, dan pasien yang menjalani operasi EPP memiliki hidup rata-rata 18,8 bulan. Tapi ketika jumlahnya dibandingkan antara pasien dengan "faktor prognostik menguntungkan" saja, tiga kelompok tersebut memiliki tingkat kelangsungan hidup yang sama, yakni 1 sampai 3 bulan. Tampak bahwa faktor seperti usia, area tumor terbatas, dan kesehatan yang baik secara keseluruhan menjadi pertanda baik bagi kelangsungan hidup tidak peduli apa pun jenis perawatan pasien.

"Data kami menunjukkan bahwa pasien dengan faktor prognosis yang baik memiliki ketahanan hidup yang sama apakah mereka menerima terapi medis saja, P/D atau EPP," para penulis melaporkan para ahli kanker paru-paru menghadiri konferensi Sydney. Karena studi ini menunjukkan bahwa operasi mesothelioma hanya menyediakan manfaat sederhana, para peneliti merekomendasikan penyelidikan lebih lanjut.
Sumber:
Bille, Andrea, et al, “Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1,365 consecutive patients”, October 29, 2013, Abstract of Oral Presentation, 15th Annual World Conference on Lung Cancer, International Association for the Study of Lung Cancer website.

About Us

    The tacklemesothelioma.blogspot.com Web Site (the "Site") is an online information service provided by Cordova Management ("tacklemesothelioma.blogspot.com "), subject to your compliance with the terms and conditions set forth below. PLEASE READ THIS DOCUMENT CAREFULLY BEFORE ACCESSING OR USING THE SITE. BY ACCESSING OR USING THE SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH BELOW. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS AND CONDITIONS, YOU MAY NOT ACCESS OR USE THE SITE. tacklemesothelioma.blogspot.com MAY MODIFY THIS AGREEMENT AT ANY TIME, AND SUCH MODIFICATIONS SHALL BE EFFECTIVE IMMEDIATELY UPON POSTING OF THE MODIFIED AGREEMENT ON THE SITE. YOU AGREE TO REVIEW THE AGREEMENT PERIODICALLY TO BE AWARE OF SUCH MODIFICATIONS AND YOUR CONTINUED ACCESS OR USE OF THE SITE SHALL BE DEEMED YOUR CONCLUSIVE ACCEPTANCE OF THE MODIFIED AGREEMENT.

1. Copyright, Licenses and Idea Submissions.

    The entire contents of the Site are protected by international copyright and trademark laws. The owner of the copyrights and trademarks are tacklemesothelioma.blogspot.com, its affiliates or other third party licensors. YOU MAY NOT MODIFY, COPY, REPRODUCE, REPUBLISH, UPLOAD, POST, TRANSMIT, OR DISTRIBUTE, IN ANY MANNER, THE MATERIAL ON THE SITE, INCLUDING TEXT, GRAPHICS, CODE AND/OR SOFTWARE. You may print and download portions of material from the different areas of the Site solely for your own non-commercial use provided that you agree not to change or delete any copyright or proprietary notices from the materials. You agree to grant to tacklemesothelioma.blogspot.com a non-exclusive, royalty-free, worldwide, perpetual license, with the right to sub-license, to reproduce, distribute, transmit, create derivative works of, publicly display and publicly perform any materials and other information (including, without limitation, ideas contained therein for new or improved products and services) you submit to any public areas of the Site (such as bulletin boards, forums and newsgroups) or by e-mail to tacklemesothelioma.blogspot.com by all means and in any media now known or hereafter developed. You also grant to tacklemesothelioma.blogspot.com the right to use your name in connection with the submitted materials and other information as well as in connection with all advertising, marketing and promotional material related thereto. You agree that you shall have no recourse against tacklemesothelioma.blogspot.com for any alleged or actual infringement or misappropriation of any proprietary right in your communications to tacklemesothelioma.blogspot.com.

TrafficServer 1.01 TRADEMARKS.

    Publications, products, content or services referenced herein or on the Site are the exclusive trademarks or servicemarks of tacklemesothelioma.blogspot.com. Other product and company names mentioned in the Site may be the trademarks of their respective owners.

2. Use of the Site.

    You understand that, except for information, products or services clearly identified as being supplied by tacklemesothelioma.blogspot.com, tacklemesothelioma.blogspot.com does not operate, control or endorse any information, products or services on the Internet in any way. Except for tacklemesothelioma.blogspot.com- identified information, products or services, all information, products and services offered through the Site or on the Internet generally are offered by third parties, that are not affiliated with tacklemesothelioma.blogspot.com a. You also understand that tacklemesothelioma.blogspot.com cannot and does not guarantee or warrant that files available for downloading through the Site will be free of infection or viruses, worms, Trojan horses or other code that manifest contaminating or destructive properties. You are responsible for implementing sufficient procedures and checkpoints to satisfy your particular requirements for accuracy of data input and output, and for maintaining a means external to the Site for the reconstruction of any lost data.

    YOU ASSUME TOTAL RESPONSIBILITY AND RISK FOR YOUR USE OF THE SITE AND THE INTERNET. tacklemesothelioma.blogspot.com PROVIDES THE SITE AND RELATED INFORMATION "AS IS" AND DOES NOT MAKE ANY EXPRESS OR IMPLIED WARRANTIES, REPRESENTATIONS OR ENDORSEMENTS WHATSOEVER (INCLUDING WITHOUT LIMITATION WARRANTIES OF TITLE OR NONINFRINGEMENT, OR THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE) WITH REGARD TO THE SERVICE, ANY MERCHANDISE INFORMATION OR SERVICE PROVIDED THROUGH THE SERVICE OR ON THE INTERNET GENERALLY, AND tacklemesothelioma.blogspot.com SHALL NOT BE LIABLE FOR ANY COST OR DAMAGE ARISING EITHER DIRECTLY OR INDIRECTLY FROM ANY SUCH TRANSACTION. IT IS SOLELY YOUR RESPONSIBILITY TO EVALUATE THE ACCURACY, COMPLETENESS AND USEFULNESS OF ALL OPINIONS, ADVICE, SERVICES, MERCHANDISE AND OTHER INFORMATION PROVIDED THROUGH THE SERVICE OR ON THE INTERNET GENERALLY. tacklemesothelioma.blogspot.com DOES NOT WARRANT THAT THE SERVICE WILL BE UNINTERRUPTED OR ERROR-FREE OR THAT DEFECTS IN THE SERVICE WILL BE CORRECTED.

    YOU UNDERSTAND FURTHER THAT THE PURE NATURE OF THE INTERNET CONTAINS UNEDITED MATERIALS SOME OF WHICH ARE SEXUALLY EXPLICIT OR MAY BE OFFENSIVE TO YOU. YOUR ACCESS TO SUCH MATERIALS IS AT YOUR RISK. tacklemesothelioma.blogspot.com HAS NO CONTROL OVER AND ACCEPTS NO RESPONSIBILITY WHATSOEVER FOR SUCH MATERIALS.

    LIMITATION OF LIABILITY

    IN NO EVENT WILL tacklemesothelioma.blogspot.com BE LIABLE FOR (I) ANY INCIDENTAL, CONSEQUENTIAL, OR INDIRECT DAMAGES (INCLUDING, BUT NOT LIMITED TO, DAMAGES FOR LOSS OF PROFITS, BUSINESS INTERRUPTION, LOSS OF PROGRAMS OR INFORMATION, AND THE LIKE) ARISING OUT OF THE USE OF OR INABILITY TO USE THE SERVICE, OR ANY INFORMATION, OR TRANSACTIONS PROVIDED ON THE SERVICE, OR DOWNLOADED FROM THE SERVICE, OR ANY DELAY OF SUCH INFORMATION OR SERVICE. EVEN IF tacklemesothelioma.blogspot.com OR ITS AUTHORIZED REPRESENTATIVES HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, OR (II) ANY CLAIM ATTRIBUTABLE TO ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE SERVICE AND/OR MATERIALS OR INFORMATION DOWNLOADED THROUGH THE SERVICE. BECAUSE SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES, THE ABOVE LIMITATION MAY NOT APPLY TO YOU. IN SUCH STATES, tacklemesothelioma.blogspot.com LIABILITY IS LIMITED TO THE GREATEST EXTENT PERMITTED BY LAW.

    tacklemesothelioma.blogspot.com makes no representations whatsoever about any other web site which you may access through this one or which may link to this Site. When you access a non-tacklemesothelioma.blogspot.com web site, please understand that it is independent from tacklemesothelioma.blogspot.com, and that tacklemesothelioma.blogspot.com has no control over the content on that web site. In addition, a link to a tacklemesothelioma.blogspot.com web site does not mean that tacklemesothelioma.blogspot.com endorses or accepts any responsibility for the content, or the use, of such web site.

3. Indemnification.

    You agree to indemnify, defend and hold harmless tacklemesothelioma.blogspot.com, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Service from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation of this Agreement (including negligent or wrongful conduct) by you or any other person accessing the Service.

4. Third Party Rights.

    The provisions of paragraphs 2 (Use of the Service), and 3 (Indemnification) are for the benefit of tacklemesothelioma.blogspot.com and its officers, directors, employees, agents, licensors, suppliers, and any third party information providers to the Service. Each of these individuals or entities shall have the right to assert and enforce those provisions directly against you on its own behalf.

5.Term; Termination.

    This Agreement may be terminated by either party without notice at any time for any reason. The provisions of paragraphs 1 (Copyright, Licenses and Idea Submissions), 2 (Use of the Service), 3 (Indemnification), 4 (Third Party Rights) and 6 (Miscellaneous) shall survive any termination of this Agreement.

6.Miscellaneous.

    This Agreement shall all be governed and construed in accordance with the laws of Indonesia applicable to agreements made and to be performed in Indonesia. You agree that any legal action or proceeding between tacklemesothelioma.blogspot.com and you for any purpose concerning this Agreement or the parties' obligations hereunder shall be brought exclusively in a federal or state court of competent jurisdiction sitting in Indonesia . Any cause of action or claim you may have with respect to the Service must be commenced within one (1) year after the claim or cause of action arises or such claim or cause of action is barred. tacklemesothelioma.blogspot.com's failure to insist upon or enforce strict performance of any provision of this Agreement shall not be construed as a waiver of any provision or right. Neither the course of conduct between the parties nor trade practice shall act to modify any provision of this Agreement. tacklemesothelioma.blogspot.com may assign its rights and duties under this Agreement to any party at any time without notice to you.

Any rights not expressly granted herein are reserved.